Instil Bio is a biotechnology company pursuing a strategy of acquiring and in-licensing novel therapeutic candidates to develop treatments for diseases with significant unmet medical need. The company previously advanced cell therapy and bispecific antibody programs targeting cancer, and operates a clinical and commercial manufacturing facility leased to a pharmaceutical partner, while maintaining research operations and corporate headquarters across multiple locations. Instil Bio generates revenue through its manufacturing facility lease and aims to compete in the highly competitive biotechnology industry by navigating complex regulatory pathways, obtaining patent protection, and ultimately bringing approved therapies to market through third-party payors and healthcare systems.